Philanthropy

Chester Dudley was diagnosed with autism at 5 years old. When he reached his late teens, his mother had growing concern about the resources that would be available for him once he entered adulthood. Fortunately, Seattle Children’s Alyssa Burnett Adult Life Center made the transition for Chester easier.

When Chester Dudley was 3 years old, his mother, Stella Ogiale, enrolled him into a child care center located near their home in Philadelphia, Pennsylvania.

After a few months, Ogiale received a startling message from the center telling her that there might be something wrong with Chester.

“They told me I needed to get him checked,” Ogiale said. “When I heard that, I became so emotional and upset that I stopped taking him there.”

She thought her son’s hyperactive behavior was like any other child’s, but to give her peace of mind, she decided to have him evaluated.

Read full post »

In honor of Autism Awareness Month, On the Pulse shares a story about a mother with 3-year-old twin daughters who have autism and her showing of gratitude for the relentless care and support that the Seattle Children’s Autism Center staff has provided her family.

Nataly Cuzcueta felt like a proud parent when she witnessed her twin daughters, Kira and Aliya, smile, laugh and walk for the first time.

Seeing them reach these milestones left no doubt in Cuzcueta’s mind that their development was right on track.

However, when her daughters turned 11 months old, everything changed.

Read full post »

Miguel Navarro is finally getting back to doing what he loves most: driving.

“Driving has always been an escape for me,” said Miguel. “It’s where I feel most at home. When you’re driving, you forget everything else around you.”

Miguel’s family and care team supported him in the grandstands of the speedway. They each adorned a shirt that said, “Miguel’s Pit Crew.”

When he was first diagnosed with cancer, Miguel was told he may never be able to drive again. It was a reality he couldn’t comprehend or accept.

“I knew I’d drive again,” said Miguel. “I always knew I’d get through this.”

He promised himself he’d get behind the wheel again, and recently, he realized that dream in a special way, thanks to Seattle Children’s.

In the grandstands of Pacific Raceways, Miguel’s family, along with his care team, beamed with pride at the sight of Miguel zooming around the race track. Adorning t-shirts that read, “Miguel’s Pit Crew,” they cheered him on. Read full post »

Harper Beare was diagnosed with acute lymphoblastic leukemia when she was just 10 months old. After she wasn’t able to achieve remission through conventional treatment, she traveled to Seattle Children’s to participate in the PLAT-05 T-cell immunotherapy trial. Soon after, Harper was in remission.

Seattle Children’s doctors and researchers continue to believe chimeric antigen receptor (CAR) T-cell immunotherapy has the power to revolutionize pediatric cancer care. Over the past year, they have made tremendous progress with the promising therapy, which has given patients like Harper Beare, Erin Cross and Milton Wright a second chance at life.

Seattle Children’s recently enrolled its 200th immunotherapy patient, and now has nine T-cell therapy trials targeting childhood cancers from leukemia to solid tumors, which is one of the most robust pipelines in the country.

Seattle Children’s researchers are continuously discovering new best practices based on their experience in the trials, and as a result, will share six abstracts this weekend at the American Society of Hematology (ASH) Annual Meeting in San Diego.

“It’s amazing to be at a place in our research where we’re learning from our existing trials, and immediately incorporating that vital intel into our new trials,” said Dr. Rebecca Gardner, oncologist at Seattle Children’s and principal investigator for the PLAT-02 and PLAT-05 CAR T-cell immunotherapy trials. “We are also pleased to now offer several new trials to patients who would otherwise be out of treatment options. Our goal is to offer the best therapy possible, and to never let any patient reach the end of the line.”

Read full post »

At age 2, Erin Cross was diagnosed with acute lymphoblastic leukemia. She achieved remission through her initial cancer treatments, but relapsed in 2016. Out of treatment options, her family found hope in Seattle Children’s PLAT-02 T-cell immunotherapy clinical trial. Erin, now 8, just celebrated her two-year anniversary of being cancer-free. Photo by Jane Mann

Each morning, 8-year-old Erin Cross springs out of bed excited to go to school. A third grader in Chester, England, she loves science and math, and imagines a future as a researcher making “potions” in a lab. She loves cracking jokes, rugby and playing make-believe games with her friends on the playground. For Erin, who spent most of her life in the hospital and away from others her age, she cherishes each day she is able to just be a kid.

“It’s amazing to see Erin back to living a normal life,” said her mother, Sarah Cross. “We’re so thankful that we’re able to enjoy time as a family doing regular things like taking picnics, playing on the beach or going to the zoo. It’s time that we never take for granted.”

Nearly three years ago, Cross faced the devastating reality that she may never see her daughter grow up. At age 2, Erin was diagnosed with acute lymphoblastic leukemia (ALL). She was able to achieve remission through her initial cancer treatments, but in 2016, her family received the shattering news that she had relapsed and was out of treatment options.

That was, until they found hope in Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) chimeric antigen receptor (CAR) T-cell immunotherapy clinical trial for children and young adults with relapsed or refractory ALL who are not likely to survive with current treatments. In July 2016, Erin’s family arrived in Seattle for the trial.

“Seattle Children’s threw us a lifeline,” said Cross. “We knew we had to get her there. We moved mountains to save our daughter’s life.”

Read full post »

Avery Berg, 13, was diagnosed with a rare brain tumor at the age of 10. She endured six weeks of radiation, five brain surgeries, and six months of high-dose chemotherapy. Avery has been cancer-free for more than a year, but her mom Kristie says that cancer immunotherapy offers hope that other children can become cancer-free without having to endure such harsh therapies.

T-cell immunotherapy continues to take center stage as one of the most promising new cancer therapies of our time. What once sounded like a dream – reprogramming a person’s own immune system to fight cancer – is remarkably becoming a reality. What’s more; doctors and researchers in our own backyard are leading the way in developing this therapy for children and young adults around the world.

From covering the opening of the first T-cell immunotherapy trial when I was an anchor at KING 5 TV, to now seeing this therapy being tested in seven open clinical trials at Seattle Children’s and applied to a variety of cancers, I’ve been amazed to watch the enormous strides researchers have made in the field over a few short years.

The results also speak for themselves – 93% of patients with relapsed or refractory acute lymphoblastic leukemia in Seattle Children’s phase 1 PLAT-02 trial achieved complete initial remission. About 50% were still in remission one year after therapy. Some patients, who were otherwise unlikely to survive with traditional therapies, are still in remission nearly five years after receiving the experimental treatment. This is encouraging news, especially since leukemias are the most common childhood cancers.

And on Oct. 12, I will witness yet another major milestone – Seattle Children’s will bring their groundbreaking therapies to a global stage. Read full post »

Dr. Seok Bee Lim has been practicing pediatric dentistry at Seattle Children’s Odessa Brown Children’s Clinic (OBCC) in the Central District for nearly 37 years. Although the neighborhood around her has changed since she started her career there, the mission of OBCC and the passion she has for caring for her patients has remained steadfast. Much like OBCC, Lim provides more than just healthcare; she’s part of the rich heritage OBCC was founded upon and the diverse community it serves.

Read full post »

Garrett Smith survived six weeks on life support in Seattle Children’s neonatal intensive care unit (NICU). Photo courtesy of Arlene Chambers Photography.

From the moment he made his entrance into the world, Garrett Smith struggled to breathe.

“We longed for that first cry as he was placed upon his momma’s chest,” said Kevin Smith, Garrett’s dad. “Unfortunately, we didn’t get to hear that cry. Instead, we saw Garrett gasping for air and making quiet whimpers.”

As doctors raced to get Garrett the air he desperately needed, they first transferred him to the neonatal intensive care unit (NICU) at the hospital where he was born. When his condition continued to deteriorate, they transferred him to a higher level of care at Swedish First Hill. Less than 24 hours later, the Smiths learned he would need yet another transfer, and faced the scariest decision they ever had to make as parents. Read full post »

Milton Wright III has returned to work at the hospital that saved his life.

Milton Wright III has only worked at Seattle Children’s for a couple months, but the hospital has been his second home for much of his life.

Milton’s childhood unfolded within Seattle Children’s walls — making friends, experiencing loss and facing death more times than he can count.

Today, Milton is back at Seattle Children’s — not as a patient, but as an employee and a symbol of hope.

“I want to do something that’s worthy of my life being saved,” Milton said.

Read full post »

At Seattle Children’s, many children and young adults with cancer are finding hope in T-cell immunotherapy – an experimental treatment that boosts a patient’s immune system and uses it to fight a disease.

Seattle Children’s researchers are leading clinical trials in which a patient’s T cells are reprogrammed to express a chimeric antigen receptor (CAR) on the surface of the cell. The CAR is like a puzzle piece that’s designed to attach perfectly to a specific antigen or marker on the surface of the cancer cell. When they attach, the CAR T cells attack the cancer cells as if they were fighting an infection.

In just five years, Seattle Children’s cancer immunotherapy program has grown tremendously to include trials that target leukemia, brain and spinal cord tumors and solid tumors. Curious how these clinical trials work? Read on to learn more about the immunotherapy clinical trial process at Seattle Children’s.

Read full post »